Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.90 |
| ▸ | RAB9A | P51151 | 7/20 | 0.90 |
| ▸ | HPGD | P15428 | 3/20 | 0.90 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.90 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.90 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.90 |
| ▸ | USP2 | O75604 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12460021 | 0.96 | RAB9A (0.96) | NPC1RAB9AHPGDSMN1; SMN2CYP1A2 | |
| SCHEMBL178426 | 0.95 | NPC1 (1.00) | NPC1RAB9AHPGDSMN1; SMN2CYP1A2 | |
| SCHEMBL3455803 | 0.95 | NPC1 (1.00) | NPC1RAB9AHPGDSMN1; SMN2CYP1A2 | |
| SCHEMBL8362540 | 0.92 | RAB9A (0.83) | NPC1RAB9AHPGDSMN1; SMN2CYP1A2 | |
| SCHEMBL241843 | 0.92 | RAB9A (0.83) | NPC1RAB9AHPGDSMN1; SMN2CYP1A2 | |
| Hydrochloric Acid SCHEMBL5614019 | 0.91 | RAB9A (0.80) | NPC1RAB9AHPGDSMN1; SMN2CYP1A2 | |
| SCHEMBL23573583 | 0.87 | RAB9A (0.75) | NPC1RAB9AHPGDSMN1; SMN2CYP1A2 | |
| SCHEMBL23573584 | 0.87 | RAB9A (0.75) | NPC1RAB9AHPGDSMN1; SMN2CYP1A2 | |
| SCHEMBL20206256 | 0.87 | RAB9A (0.69) | NPC1RAB9AHPGDSMN1; SMN2CYP1A2 | |
| SCHEMBL12771544 | 0.87 | RAB9A (0.74) | NPC1RAB9AHPGDSMN1; SMN2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2032142-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-03-11 | — | — | EP | claimed |
| WO-2007147109-A2 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-12-21 | — | — | WO | claimed |
| US-20160333011-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20160024089-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2016-01-28 | — | — | US | disclosed |
| US-20140378449-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-8889673-B2 | Triazolopyridine JAK inhibitor compounds and methods | GENENTECH, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20140038939-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2014-02-06 | — | — | US | disclosed |
| US-20120225855-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | ZHU BING-YAN (US) | 2012-09-06 | — | — | US | disclosed |
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | ONCOTHERAPY SCIENCE, INC. (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20100048557-A1 | Triazolopyridine JAK Inhibitor Compounds and Methods | GENENTECH, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20100035875-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. | 2010-02-11 | — | — | US | disclosed |
| WO-2009155551-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | GENENTECH, INC. (US) | 2009-12-23 | — | — | WO | disclosed |
| CN-101128434-A | Amide derivatives | ASTRAZENECA AB (SE) | 2008-02-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059162-A1 | FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION | NR0B1, GRK7, NR5A2 | NPC1 1892/4885RAB9A 3030/4885HPGD 4110/4885 |
| US-20140378449-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | NPC1 3726/4885RAB9A 1534/4885HPGD 2150/4885 |
| US-20100048557-A1 | Triazolopyridine JAK Inhibitor Compounds and Methods | JAK2, JAK1, JAK3 | NPC1 3726/4885RAB9A 1534/4885HPGD 2150/4885 |
| US-20160024089-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | NPC1 3726/4885RAB9A 1534/4885HPGD 2150/4885 |
| US-20160333011-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK1, JAK2, JAK3 | NPC1 3307/4885RAB9A 1441/4885HPGD 2955/4885 |
| US-20140038939-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | NPC1 3726/4885RAB9A 1534/4885HPGD 2150/4885 |
| US-20120225855-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | NPC1 3726/4885RAB9A 1534/4885HPGD 2150/4885 |
| US-20100035875-A1 | TRIAZOLOPYRIDINE JAK INHIBITOR COMPOUNDS AND METHODS | JAK2, JAK1, JAK3 | NPC1 3726/4885RAB9A 1534/4885HPGD 2150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.